Abstract
Background: Survival outcomes for advanced stage metastatic melanoma patients have significantly improved following treatment with combined CTLA-4 and PD-1 checkpoint inhibitors. Although some patients have demonstrated durable responses to immunotherapy, others derive minimal or no benefit. Phenotyping and characterising the immune cells present within and surrounding the tumour may predict response to immunotherapy and improve our understanding of the mechanisms driving differences in response between patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
